A coincidence or a rare occurrence? A case of plasmablastic lymphoma of the small intestines following infliximab treatment for Crohn’s disease

Maung, Su Wai; Desmond, Ronan; McHugh, Johnny; Ryan, Barbara; Neary, Paul; Jeffers, Michael; Enright, Helen

doi:10.1007/s00277-015-2497-6

Cited by 6 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those two cases did not previously receive any immunosuppressive therapies. On the contrary, 4 cases among 5 CD cases with PBL received preceding immunosuppressive therapies (22-26), implying that PBL is strongly related with immunosuppressive therapies as already shown before (16). The causal relationship between CD and EMP seems to be very weak, but the co-localization of EMP with active CD lesions in 3 cases including ours suggests that the pathophysiology of CD might be related with the incidence of EMP (20, 21).…”

Section: Discussionmentioning

confidence: 74%

Crohn's Disease Accompanied with Small Intestinal Extramedullary Plasmacytoma

et al. 2019

View full text Add to dashboard Cite

We herein present the case of an immunocompetent 63-year-old man who had previously undergone resection of Crohn's disease (CD)-related small intestinal obstruction more than 30 years ago. He had not been receiving any medication for many years, but had recently started to suffer from ileus. A stenosed site of ileo-cecal anastomosis was identified and therefore was surgically resected, which was diagnosed as CD with small intestinal extramedullary plasmacytoma (EMP). The subsequent progression of CD was successfully controlled by anti-TNFα agents without any recurrence of EMP for over 3 years, implying the clinical benefit and safety of the biological therapy. This was the first known case of a patient who received anti-TNFα agents after a resection of small intestinal EMP accompanied with CD.

show abstract

Section: Discussionmentioning

confidence: 74%

Crohn's Disease Accompanied with Small Intestinal Extramedullary Plasmacytoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The symptoms included bleeding, anemia, abdominal pain, and weight loss. Seven of the 19 cases, 6 men and one woman, were negative for both HIV and EBV (age range 50-85 years, median age 60 years) ( 10 - 15 ). Co-existent diseases included Crohn's disease in one ( 15 ), malignances in two ( 13 ), diabetes in one ( 14 ), and unknown disease in one patient ( 10 ).…”

Section: Discussionmentioning

confidence: 99%

“…Seven of the 19 cases, 6 men and one woman, were negative for both HIV and EBV (age range 50-85 years, median age 60 years) ( 10 - 15 ). Co-existent diseases included Crohn's disease in one ( 15 ), malignances in two ( 13 ), diabetes in one ( 14 ), and unknown disease in one patient ( 10 ). The other 2 cases had no co-existent diseases that were recognized ( 11 , 12 ).…”

Section: Discussionmentioning

confidence: 99%

“…Of the remaining 7 of the 19 patients, whether they had either EBV or HIV infection was not clear ( 2 , 3 , 16 - 18 ). Six of the 19 cases survived for more than a year ( 3 , 12 , 15 ); 1 was HIV positive ( 3 ), 4 were HIV negative ( 3 , 12 , 15 ), and the HIV status was unknown in 1 case ( 3 ). Of those 6 patients, 2 had chemotherapy and surgery ( 3 , 15 ) and 4 had only chemotherapy ( 3 , 12 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasmablastic Lymphoma of the Small Intestine in an HIV- and EBV-negative Patient

et al. 2021

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a rare aggressive B-cell lymphoproliferative disorder that is strongly associated with immunodeficiency, most often with human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) infection, and that mainly occurs in the oral cavity. Although some clinical features can lead to a diagnosis, PBL in an extraoral site is difficult to suspect clinically in a patient who is HIV negative. The small intestine as a site of PBL has also been described very rarely. We herein present a rare case of PBL of the small intestine in an 85-year-old HIV- and EBV-negative male.

show abstract

Plasmablastic lymphoma occurring in ulcerative colitis during treatment with immunosuppressive therapy

Ogiyama

Murayama

Tsutsui

et al. 2023

Clin J Gastroenterol

View full text Add to dashboard Cite

A 53-year-old man who had a history of ulcerative colitis (UC) for 2 years underwent colonoscopy as regular follow-up. The results showed an elevated lesion in the descending colon, which was diagnosed as plasmablastic lymphoma (PBL) based on pathological findings. In situ hybridization for the Epstein–Barr virus-encoded RNA probe was positive. Fluorescence in situ hybridization revealed rearrangement of the MYC gene. He had been taking prednisolone, 5-aminosalicylic acid, azathiopurine, and ustekinumab at the diagnosis of PBL and had multiple prior therapies for UC including infliximab, tacrolimus, and tofacitinib due to steroid dependence. PBL is a rare aggressive B cell lymphoma initially described in the oral cavity of human immunodeficiency virus positive patients and it is suspected to have an association with immunocompromised status of patients. The number of cases of PBL in inflammatory bowel disease (IBD) patients is extremely rare. All these patients were administered immunosuppressive therapy including thiopurines or biologics. IBD patients with immunosuppressive therapy have a higher potential for developing lymphoproliferative disorders. Clinicians should be aware of the risk of lymphoma, including PBL.

show abstract

A coincidence or a rare occurrence? A case of plasmablastic lymphoma of the small intestines following infliximab treatment for Crohn’s disease

Cited by 6 publications

References 6 publications

Crohn's Disease Accompanied with Small Intestinal Extramedullary Plasmacytoma

Crohn's Disease Accompanied with Small Intestinal Extramedullary Plasmacytoma

Plasmablastic Lymphoma of the Small Intestine in an HIV- and EBV-negative Patient

Plasmablastic lymphoma occurring in ulcerative colitis during treatment with immunosuppressive therapy

Contact Info

Product

Resources

About